BiotechTube
Intrommune Therapeutics

Intrommune Therapeutics

New York, United States· Est.
intrommune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Intrommune Therapeutics is a clinical-stage biotech developing a disruptive drug delivery platform for food allergy immunotherapy. Its lead program, INT301, encapsulates allergenic proteins in a toothpaste, enabling daily treatment through routine brushing to desensitize patients via the oral mucosa. The company is targeting a large and growing unmet medical need with a treatment designed to improve adherence and quality of life over current burdensome options. Led by a management team with legal, financial, and clinical expertise, Intrommune is advancing its OMIT platform through clinical development.

Allergy & ImmunologyFood Allergy

Technology Platform

Oral Mucosal Immunotherapy (OMIT) platform delivering allergenic proteins via a specially formulated, fully functional toothpaste for daily administration through brushing.

Funding History

2
Total raised:$15M
Series A$12M
Seed$3M

Opportunities

The large and growing unmet need in food allergy, with over 33 million patients in the U.S.
alone, presents a massive market.
Intrommune's convenient, adherence-friendly toothpaste format could capture significant share from current burdensome therapies.
The platform's adaptability to multiple allergens offers a broad pipeline and potential for expansion into other mucosal immunotherapies.

Risk Factors

High clinical development risk: the novel OMIT mechanism must prove effective and safe in human trials.
Regulatory pathway for a drug-toothpaste combination product may be complex.
Competition from other immunotherapy approaches (OIT, patches, biologics) and potential financing challenges as a private, pre-revenue company.

Competitive Landscape

Competitors include Aimmune Therapeutics (now Nestlé Health Science) with the approved OIT product Palforzia for peanut allergy, and DBV Technologies developing an epicutaneous (patch) delivery system. Intrommune's primary differentiation is its unique delivery method targeting the oral mucosa via a daily hygiene routine, aiming for better adherence and a favorable safety profile.

More companies in Drug Delivery & Formulation →More companies in United States →